Drug Clinical Trials List

Study Title	Study Sponsor	Status	Study Drug	Trial Phase	Study Protocol Number	Site
Long-term pain and adherence observational study for Endometriosis treatment	Abbott	Ongoing	Duphaston	4	DYDR-522-0318	Dr.Arab Clinic
Real world Assessment of Dyslipidemia patients on Inclisiran effiCacy And toLerability: The RADICAL Study	Novartis	Ongoing	LEQVIO	4	CKJX839A1S	Dallah Hospital (Riyadh)
Effect of celecoxib on postoperative narcotic use and disease severity in patients with aspirin-exacerbated respiratory disease and chronic rhinosinusitis: a randomized controlled trial	King Khalid University Hospital	Ongoing	Celecoxib	4	114809	King Khalid University Hospital (Riyadh) King Abdulaziz University Hospital (Riyadh)
EASi-HF - A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) >40%	Boehringer Ingelheim	Ongoing	BI 690517 , empagliflozin	3	1378-0020	King Fahad Medical City (Riyadh), King Khalid University Hospital (Riyadh), King Faisal Specialist Hospital and Research Center (Riyadh)
Effect of Probiotics “Psychobiotics” on Depression in Adults with Obesity and Metabolic Syndrome in Riyadh City	King Khalid University Hospital	Ongoing	Winclove’s Ecologic® Barrier probiotics	3	E-23-7867	King Khalid University Hospital (Riyadh)
BalanceD-HF: A Phase III, Randomised, Double-blind Study to Evaluate the Effect of Balcinrenone/Dapagliflozin, Compared with Dapagliflozin, on the Risk of Heart Failure Events and Cardiovascular Death in Patients with Heart Failure and Impaired Kidney Function	AstraZeneca	Ongoing	balcinrenone/dapagliflozin	3	D6402C00012	King Faisal Specialist Hospital and Research Center (Riyadh), King Abdulaziz Medical City NG (Riyadh)
A Phase 3 Randomized, Placebo-Controlled, Double-Blind, Multicenter Study to Evaluate the Efficacy and Safety of Nipocalimab in Pregnancies at Risk for Severe Hemolytic Disease of the Fetus and Newborn (HDFN)	Janssen Research & Development	Rejected	Nipocalimab	3	80202135EBF3001	King Faisal Specialist Hospital and Research Center (Riyadh) ,King Saud Medical City (Riyadh), King Fahad University Hospital (Al-Khobar)
Phase 3b, Open-label, Multicenter, Single-dose Study Investigating Efficacy and Safety of CSL222 (Etranacogene Dezaparvovec) Gene Therapy Administered to Adult Subjects with Severe or Moderately Severe Hemophilia B with Detectable Pretreatment AAV5 Neutralizing Antibodies	CSL Behring LLC	Ongoing	HEMGENIX (etranacogene dezaparvovec)	3b	CSL222_3005	King Faisal Specialist Hospital and Research Center (Riyadh)
REAL-WORLD, LONG-TERM DATA COLLECTION TO GAIN CLINICAL INSIGHTS INTO ROCHE OPHTHALMOLOGY PRODUCTS (VOYAGER STUDY)- COMPLETE	Roche	Ongoing	Vabysmo	4	MR41927	King Abdulaziz Medical City NG (Jeddah)
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Ravulizumab in Adult Participants with Immunoglobulin A Nephropathy (IgAN)	AstraZeneca	Ongoing	Ravulizumab	3	D928FC00001	King Faisal Specialist Hospital and Research Center (Riyadh)